{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:34:54Z","timestamp":1780389294544,"version":"3.54.1"},"reference-count":10,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"DOI":"10.1111\/bju.70253","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:31:19Z","timestamp":1773822679000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate\u2010specific membrane antigen (\n                    <scp>PSMA)<\/scp>\n                    \u2010\n                    <scp>PET<\/scp>\n                    \u2010avid prostate cancers show stronger\n                    <scp>PSMA<\/scp>\n                    immunohistochemistry staining on biopsy cores"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0948-6468","authenticated-orcid":false,"given":"Jonathon","family":"Carll","sequence":"first","affiliation":[{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare  Melbourne Victoria Australia"},{"name":"Department of Urology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Surgery University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry Yen\u2010Cheng","family":"Pan","sequence":"additional","affiliation":[{"name":"Department of Urology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Surgery University of Melbourne  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Lawrentschuk","sequence":"additional","affiliation":[{"name":"EJ Whitten Prostate Cancer Research Centre, Epworth Healthcare  Melbourne Victoria Australia"},{"name":"Department of Urology The Royal Melbourne Hospital  Melbourne Victoria Australia"},{"name":"Department of Surgery University of Melbourne  Melbourne Victoria Australia"},{"name":"Department of Cancer Surgery Peter MacCallum Cancer Centre  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Ryan","sequence":"additional","affiliation":[{"name":"TissuPath Pathology  Melbourne Victoria Australia"},{"name":"Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","article-title":"Is prostate\u2010specific membrane antigen positron emission tomography\/computed tomography imaging cost\u2010effective in prostate cancer: an analysis informed by the proPSMA trial","volume":"79","author":"Feria Cardet RE","year":"2021","journal-title":"Eur Urol"},{"key":"e_1_2_6_3_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/bju.15664","article-title":"The clinical characteristics of patients with primary non\u2010prostate\u2010specific membrane antigen\u2010expressing prostate cancer on preoperative positron emission tomography\/computed tomography","volume":"129","author":"Veerman H","year":"2022","journal-title":"BJU Int"},{"key":"e_1_2_6_4_1","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/bju.70015","article-title":"The role of PSMA PET\/CT in staging patients with intermediate\u2010risk prostate cancer","volume":"137","author":"Bonaddio J","year":"2025","journal-title":"BJU Int"},{"key":"e_1_2_6_5_1","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1007\/s00259-021-05501-1","article-title":"What's behind (68)Ga\u2010PSMA\u201011 uptake in primary prostate cancer PET? Investigation of histopathological parameters and immunohistochemical PSMA expression patterns","volume":"48","author":"R\u00fcschoff JH","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2967\/jnumed.117.195172","article-title":"Immunohistochemical validation of PSMA expression measured by 68 Ga\u2010PSMA PET\/CT in primary prostate cancer","volume":"59","author":"Woythal N","year":"2018","journal-title":"J Nucl Med"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1324631","article-title":"Immunohistochemistry analysis of PSMA expression at prostatic biopsy in high\u2010risk prostate cancer: potential implications for PSMA\u2010PET patient selection","volume":"14","author":"Droghetti M","year":"2024","journal-title":"Front Oncol"},{"key":"e_1_2_6_8_1","article-title":"Immunohistochemical prostate\u2010specific membrane antigen (PSMA) expression patterns of primary prostate cancer tissue as a determining factor for prostate cancer staging with PSMA positron emission tomography\/computed tomography","volume":"2588","author":"Ambrosini F","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"e_1_2_6_9_1","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fonc.2018.00623","article-title":"Expression of prostate\u2010specific membrane antigen (PSMA) on biopsies is an independent risk Stratifier of prostate cancer patients at time of initial diagnosis","volume":"8","author":"Hupe MC","year":"2018","journal-title":"Front Oncol"},{"key":"e_1_2_6_10_1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.eururo.2019.06.030","article-title":"Prostate\u2010specific membrane antigen heterogeneity and DNA repair defects in prostate cancer","volume":"76","author":"Paschalis A","year":"2019","journal-title":"Eur Urol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00259-024-06856-x","article-title":"Immunohistochemical ERG positivity is associated with decreased PSMA expression and lower visibility in corresponding [(68)Ga]Ga\u2010PSMA\u201011 PET scans of primary prostate cancer","volume":"52","author":"Rupp NJ","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70253","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bju.70253","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.70253","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T08:31:22Z","timestamp":1773822682000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.70253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":10,"alternative-id":["10.1111\/bju.70253"],"URL":"https:\/\/doi.org\/10.1111\/bju.70253","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"2026-03-18","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"bju.70253"}}